Clinical Trial Update: Immunogenicity After Revaccination With 23-valent Pneumococcal Polysaccharide Vaccine: Healthy Elderly People Versus Diabetic Patients [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing immunogenicity after revaccination with the 23-valent pneumococcal polysaccharide vaccine between healthy elderly individuals a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• 23-valent pneumococcal polysaccharide vaccine (Pneumococcal polysaccharide vaccine 23-valent)

Snippet

Sponsor: Korea University Guro Hospital | Conditions: Pneumococcal Infections | Phase 4 | Status: UNKNOWN